Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
In conclusion, lusutrombopag may be a useful drug for patients with thrombocytopenia to avoid platelet transfusion in those undergoing two or more planned invasive procedures.
PMID: 28943563 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Internal Medicine | Liver | Liver Cancer | Liver Disease | Thrombocytopenia | Urology & Nephrology